To further elucidate the mechanistic basis of how KK2DP7 activates these CD11b+ cells for anti‐tumor activity, we conducted transcriptome and ATAC sequencing studies, along with validation experiments, on CD11b+ cells isolated after immune training with KK2DP7. The gene discussed is ITGAM; the disease is neoplasm.